Abstract
Background:The O6-methylguanine-DNA methyltransferase (MGMT) gene prevents mismatch in DNA replication and transcription by repairing mutagenic DNA lesions. MGMT is a predictor biomarker of chemotherapy in high-grade and low-grade gliomas based on high-risk clinical conditions. It also can be used for therapeutic decisions to predict hypermutation in recurrence in newly diagnosed low-grade gliomas. The gold standard examination for the methylation is Polymerase Chain Reaction (PCR). However, this technique is not widely available in Indonesia for daily practice. Thus, an uncomplicated and simpler method such as immunohistochemistry (IHC) is needed as an alternative examination. This study aimed to predict the diagnostic accuracy of immunohistochemistry (IHC) in detecting the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) in glioma. Methods:This research was a cross-sectional study using formalin-fixed paraffin embedded (FFPE) tissue samples of glioma patients, dating between October 2017 until March 2021. Diagnosis of glioma was established based on clinical, radiological, and histopathological findings. MGMT methylation status was investigated using the IHC and PCR techniques. Diagnostic value of IHC was analyzed, with PCR as a gold standard method. Optimum threshold to determine positivity of IHC was determined by the Area Under the Curve (AUC) on Receiver Operating Characteristics (ROC) curve and Youden index. Results:Among 75 samples examined, 29 (38.7%) patients were methylated. IHC detected MGMT methylation with sensitivity of 86.2%, specificity of 63.0%, positive predictive value of 59.5%, negative predictive value of 87.9% and accuracy of 72.0%. The AUC was 0.746, indicating moderate diagnostic value. Optimum positivity threshold of the IHC examination based on Youden Index was 10%. Conclusion:IHC examination can be used to detect MGMT methylation status of glioma patients in limited resources setting, where PCR technique is not available.
Highlights
Glioma is the most often found primary intracranial tumor with the highest incidences occurring in Europe (5.5 per 100,000 population), North America (5.3 per 100,000 population), Australia (5.3 per 100,000 population), North Africa (5 per 100,000 population) and West Asia (5.2 per 100,000 population)
methylguanine-DNA methyltransferase (MGMT) promoter methylation was identified in 38.7% of the samples, which was less than the unmethylated ones
MGMT methylation was mostly found in grade IV of glioma which is similar with previous research that showed high methylation status in glioblastoma (WHO grade IV) (Wang et al, 2017)
Summary
Glioma is the most often found primary intracranial tumor with the highest incidences occurring in Europe (5.5 per 100,000 population), North America (5.3 per 100,000 population), Australia (5.3 per 100,000 population), North Africa (5 per 100,000 population) and West Asia (5.2 per 100,000 population). MGMT is a predictor biomarker of chemotherapy in high-grade and low-grade gliomas based on high-risk clinical conditions. The gold standard examination for the methylation is Polymerase Chain Reaction (PCR). This technique is not widely available in Indonesia for daily practice. This study aimed to predict the diagnostic accuracy of immunohistochemistry (IHC) in detecting the methylation status of O6-methylguanine-DNA methyltransferase (MGMT) in glioma. MGMT methylation status was investigated using the IHC and PCR techniques. Diagnostic value of IHC was analyzed, with PCR as a gold standard method. Conclusion: IHC examination can be used to detect MGMT methylation status of glioma patients in limited resources setting, where PCR technique is not available
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
